<p>美国银行证券分析师 Sachin Jain 重申了对 NOVN 股票的看涨态度，并在 12 月 8 日给予买入评级。</p>
<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Sachin Jain 给予买入评级的原因是多种因素的结合，突显了诺华制药（Novartis AG）在增长和创新方面的强大潜力。该公司在激素治疗市场上表现稳健，特别是其药物 Kisqali，预计将在没有直接竞争的情况下与其他疗法一起表现良好。此外，诺华积极参与战略合作，以增强 Kisqali 与其他治疗的联合疗效，这可能显著提升其市场地位。</p>
<p>此外，诺华在心血管项目上也展现出潜力，特别是在 Pelacarsen 方面，公司对实现心血管风险因素的显著降低持乐观态度。对其用于复发性多发性硬化症（RRMS）的 remibrutinib 治疗的信心，以及其良好的安全性和有效性进一步支持了积极的前景。公司的战略收购，如 Avidity，也被视为潜在的数十亿美元机会，因预期的长期利益和市场扩展而强化了买入评级。</p>
<p>在 12 月 8 日发布的另一份报告中，摩根大通也将该股票升级为买入，目标价为 CHF125.00。</p>

诺华制药

<p>美国银行证券分析师 Sachin Jain 重申了对诺华制药的买入评级，指出其强劲的增长潜力和战略创新。关键因素包括 Kisqali 在激素治疗市场的成功、战略合作伙伴关系、与 Pelacarsen 的心血管项目，以及针对复发性多发性硬化症（RRMS）的有前景的治疗方案如 remibrutinib。战略收购，如 Avidity，被视为数十亿美元的机会。摩根大通也将该股票评级上调至买入，目标价为 125.00 瑞士法郎</p>

<p>Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on NOVN stock, giving a Buy rating on December 8.</p>
<div class="lb-trans"><p>美国银行证券分析师 Sachin Jain 重申了对 NOVN 股票的看涨态度，并在 12 月 8 日给予买入评级。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Sachin Jain has given his Buy rating due to a combination of factors that highlight Novartis AG’s strong potential for growth and innovation. The company has demonstrated a solid position in the hormonal therapy market, particularly with its drug Kisqali, which is expected to perform well alongside other therapies without direct competition. Furthermore, Novartis is actively engaged in strategic partnerships to enhance the efficacy of Kisqali in combination with other treatments, which could significantly bolster its market presence.</p>
<div class="lb-trans"><p>Sachin Jain 给予买入评级的原因是多种因素的结合，突显了诺华制药（Novartis AG）在增长和创新方面的强大潜力。该公司在激素治疗市场上表现稳健，特别是其药物 Kisqali，预计将在没有直接竞争的情况下与其他疗法一起表现良好。此外，诺华积极参与战略合作，以增强 Kisqali 与其他治疗的联合疗效，这可能显著提升其市场地位。</p>
</div><p>Additionally, Novartis shows promise in its cardiovascular initiatives, particularly with Pelacarsen, where the company is optimistic about achieving meaningful reductions in cardiovascular risk factors. The confidence in its remibrutinib treatment for RRMS, with favorable safety and efficacy profiles, further supports the positive outlook. The company’s strategic acquisitions, such as Avidity, are also seen as potential multi-billion dollar opportunities, reinforcing the Buy rating due to the anticipated long-term benefits and market expansion.</p>
<div class="lb-trans"><p>此外，诺华在心血管项目上也展现出潜力，特别是在 Pelacarsen 方面，公司对实现心血管风险因素的显著降低持乐观态度。对其用于复发性多发性硬化症（RRMS）的 remibrutinib 治疗的信心，以及其良好的安全性和有效性进一步支持了积极的前景。公司的战略收购，如 Avidity，也被视为潜在的数十亿美元机会，因预期的长期利益和市场扩展而强化了买入评级。</p>
</div><p>In another report released on December 8, J.P. Morgan also upgraded the stock to a Buy with a CHF125.00 price target.</p>
<div class="lb-trans"><p>在 12 月 8 日发布的另一份报告中，摩根大通也将该股票升级为买入，目标价为 CHF125.00。</p>
</div>

Novartis AG: Strong Growth Potential and Strategic Innovations Justify Buy Rating

- 美银证券分析师 Sachin Jain 重申对 NOVN 股票的看涨评级，给予买入评级。  
- Novartis AG 在激素治疗市场表现强劲，Kisqali 药物前景良好。  
- J.P. Morgan 也在同日将该股票评级上调至买入，目标价为 CHF125.00。

诺华制药：强劲的增长潜力和战略创新为买入评级提供了合理依据